Introduction Intraductal papillary mucinous neoplasms (IPMNs) of the pancreas are precursor lesions that progress to invasive cancer through progressively worsening dysplasia. Although smoking is an established risk factor for pancreatic adenocarcinoma, potential associations with IPMN grade of dysplasia remain unclear. Methods Pancreatic resections for IPMN from 1995 to 2013 were retrospectively reviewed. A total of 446 patients in which the smoking status was documented were identified. Results Smoking history was positive in 47 % of patients. Of smokers, 50 % had branch-duct, 14 % had main-duct, and 36 % had mixed-type IPMN. Patients with main-duct IPMN were more commonly smokers (65 %), compared to smoking history in 46 % with mixed and 44 % with branch-duct IPMN (p=0.03). High-grade dysplasia occurred in 25 % of smokers and 21 % of nonsmokers (p=0.32), and invasive carcinoma in 25 % of smokers and 25 % nonsmokers (p= 0.95). On multivariate analysis, duct size was independently associated with high-grade dysplasia (OR=3.17, 95 %CI= 1.79-5.64, p<0.001). Presence of mural nodules (OR =3.34, 95 %CI=1.82-6.12, p< 0.001), duct size (OR =3.87, 95 %CI=2.21-6.75, p<0.001), and symptoms (OR=7.10, 95 %CI=3.80-13.08, p<0.001), but not smoking history (OR=1.10, p=0.73), were independent predictors of invasive carcinoma. Median overall survival was 70 months for smokers and 88 months for nonsmokers (p=0.68). Conclusion Positive smoking history correlated with duct type classification but does not appear to be a risk factor for harboring high-grade dysplasia or invasive carcinoma in IPMNs.
Introduction
Intraductal papillary mucinous neoplasms (IPMNs) are characterized by cystic dilatation of the pancreatic ducts which are lined by mucin-producing epithelial cells with columnar features, with or without papillary projection.
1 , 2 IPMN may arise in the main pancreatic ducts, side branch ducts, or both, known as main-duct type, branch-duct type, and mixed-type IPMNs, respectively.
3 -5 IPMNs are thought to progress from low-grade dysplasia to high-grade dysplasia to invasive carcinoma, analogous to the adenoma to invasive carcinoma progression of colorectal cancer. IPMNs therefore provide a unique opportunity to intervene before the development of invasive pancreatic cancer.
5 , 6 The frequency of surgically resected IPMNs harboring high-grade dysplasia and/or an associated invasive adenocarcinoma ranges significantly in different studies and is reported to be as low as 6 % in branch-duct IPMNs to as high as 92 % in main-duct IPMNs.
4 , 7 -13 Established risk factors for the development of pancreatic adenocarcinoma include family history of pancreatic cancer, tobacco exposure, diabetes mellitus, chronic pancreatitis, and obesity.
14 , 15 Some individuals with a strong family history of pancreatic cancer also appear to have an increased risk of developing an IPMN.
1 , 16 However, evidence regarding environmental risk factors for the development of IPMNs or progression to high-grade dysplasia and invasive carcinoma in existing IPMNs is lacking. 17 , 18 According to the Center for Disease Control and Prevention (CDC), the estimated general population smoking prevalence is reported to be between 18 and 21 %. 19 Smoking history has been reported to be responsible for approximately 20 % of pancreatic cancers. 15 , 20 However, the prevalence of smoking in patients with IPMN and the influence of smoking on progression of IPMN to invasive cancer is unclear. Since smoking is a well-established risk factor for the development of pancreatic adenocarcinoma, 21 we sought to determine the influence of smoking on IPMN pathology-a precursor to pancreatic adenocarcinoma. Specifically, in this study, we investigate the association of smoking with duct type, with the degree of dysplastic changes, and with surgical outcomes of patients undergoing resection of IPMN.
Materials and Methods

Study Population
This study was approved by the Johns Hopkins Institutional Review Board (IRB). A retrospective review of all patients undergoing surgical resection of IPMN at Johns Hopkins Hospital (JHH) between 1995 and 2013 was performed. We excluded patients without adequate smoking history documentation and only included patients who had at least one preoperative imaging study (CT scan, endoscopic ultrasound (EUS), or MRI) at JHH. Based on these selection criteria, a total of 446 patients were identified for analysis.
Clinicopathologic data including patient age, gender, race, smoking history, type of surgical resection, and grade of dysplasia were collected. Preoperative imaging findings analyzed were duct type, lesion size, and presence of mural nodules. Smoking history was collected through patients' records. Complications were scored by the Clavien-Dindo classification scheme with major complications being defined as Clavien grade III or more. Patients were classified as smokers if they reported ever being a habitual smoker, if they ever smoked for 6 months or longer, or if they had a smoking history of >100 cigarettes in their lifetime, and nonsmokers if they denied ever being a smoker. Patients' survival time was calculated from the time of operation to death or last followup. Patients with less than 30 days of follow-up were excluded from the survival analysis.
Intraductal Papillary Mucinous Neoplasms
Based on preoperative imaging performed at JHH, IPMNs were classified as branch-duct type IPMN, in which the cystic lesion was present without the dilation of the main pancreatic duct, as main-duct type, in which the main pancreatic duct was dilated without associated cystic lesion, and as mixed-type IPMN if the cystic lesion was present with a coexisting dilated main duct. Main duct dilation was defined as a main pancreatic duct size of 5 mm or more in any portion of the duct, and cyst size was defined as the maximal size measured on preoperative imaging. Multifocal IPMN was defined as the presence of more than one grossly separate cyst in more than one region of the pancreas. All pathologic specimens were examined by one expert pancreatic pathologist at JHH. IPMNs were defined as flat or papillary mucin containing epithelial neoplasms with involvement of the main or side branches of pancreatic duct. The highest grade of dysplasia in the lesion was considered as the IPMN Postoperative complications were observed in 242 (54 %) patients, of which 139 (57 %) were smokers and 103 (43 %) were nonsmokers (p=0.06). Severe postoperative complications occurred in 18 (9 %) smokers and 23 (10 %) nonsmokers (p=0.71). There were no differences amongst smokers and nonsmokers in terms of the rate of pancreatic fistula (PF) (16 vs. 22 %, p=0.12) and delayed gastric emptying (DGE) (12 vs. 18 %, p=0.08) after surgery (Table 1) .
On multivariate analysis, main pancreatic duct size was independently associated with the presence of high-grade dysplasia (OR 3.17, 95 % CI 1.79-5.64, p<0.001). The presence of mural nodules (OR 3.34, 95 % CI 1.82-6.12, p<0.001), main pancreatic duct size (OR 3.87, 95 % CI 2.21-6.75, p<0.001), and symptoms (OR 7.05, 95 % CI 3.80-13.08, p<0.001), but not smoking history (OR 1.10, 95 % CI 0.64-1.88, p=0.73), were independent predictors of the presence of an associated invasive carcinoma when compared to patients with low or moderate grade dysplasia (Table 2) .
Branch-Duct IPMN
The characteristics of patients with branch-duct type IPMN are summarized in Table 3 . Of branch-duct IPMNs, 122 (52 %) were male. The mean age of this group was 66.8 years (median 69, range 32-90 years).
The mean cyst size of the entire branch-duct group was 3.1 cm (range 0.5-10 cm). On pathologic assessment, lowgrade dysplasia was seen in 61 ( Among branch-duct IPMNs, after adjusting for patients' gender, age, presence of mural nodules, symptoms, and cyst size, smoking history was not found to be a risk factor for high-grade dysplasia (OR=1.22, 95 % CI=0.59-2.48, p= 0.59) or the presence of an associated invasive carcinoma (OR=0.59, 95 % CI=0.23-1.50, p=0.27) based on final pathology (Table 4) .
Main-Duct IPMN
Forty-six (10 %) patients were diagnosed with a main-duct IPMN, of which 30 (65 %) patients were smokers. Amongst 
Survival Outcomes
The median overall survival of smokers was 70 months, which was similar to those patients without smoking history who had a median overall survival of 88 months (p=0.68) (Fig. 1) . Similarly, among patients with branch-duct IPMN, survival did not correlate with smoking history (p=0.57). Among branch-duct IPMNs, the 5-year survival rate was 62 % for smokers and 68 % for nonsmokers (Fig. 2) . In mixed-type IPMNs, smoking history was associated with median survival of 66 months, which was similar to those without smoking history with median survival of 81 months (p=0.74) (Fig. 3) . Median overall survival of main-duct IPMNs was 75 months and was statistically similar in smokers and nonsmokers (p=0.62) (Fig. 4) .
Discussion
A significant body of evidence supports that IPMNs are precursor lesions of invasive pancreatic adenocarcinoma. Unlike pancreatic intraepithelial neoplasm (PanINs), IPMNs are macroscopic and present an opportunity for early treatment in individuals with this neoplasm. Approximately 70 % of mainduct type and mixed-type IPMNs have either high-grade dysplasia or an associated invasive carcinoma, and recommendations are therefore to resect all lesions with main duct involvement. 5 , 22 In contrast, the prevalence of high-grade dysplasia/associated invasive carcinoma is lower in patients with surgically resected branch-duct IPMN, and as a result, the management of these lesions is still under 23 Since smoking is a well-established risk factor for the development of pancreatic adenocarcinoma, 21 we sought to determine the influence of smoking on IPMN pathology. Despite the strong association of smoking with pancreatic cancer, we report that a positive smoking history is not statistically associated with higher incidence of high-grade dysplasia or invasive carcinoma in patients who underwent pancreatic resection for IPMN. To our knowledge, this study is the first to directly evaluate this question in surgically resected IPMNs with pathologic confirmation of the grades of dysplasia. A potential shortcoming of our study is that all subjects were selected for surgical resection and the patients believed to have IPMN that were not selected for resection are difficult to capture in a retrospective study. We found, however, that smoking history was more prevalent among patients who underwent resection for main-duct type IPMN. Interestingly, while smoking history is an important cause of pancreatic adenocarcinoma, our results do not demonstrate a correlation between smoking history and development of invasive carcinoma or high-grade dysplasia in patients with IPMN lesions. These findings, along with the others investigating IPMN risk factors, indicate that smoking history cannot be used to predict the risk of high-grade dysplasia/associated invasive carcinoma in patients with a known IPMN.
Our results, which uniquely focus on resected patients, are consistent with the work of others on IPMN and smoking. In a case-control study by Baumgaertner et al. 24 smoking history was not found to be a risk factor for the development of IPMN. Another case-control study by Capurso et al. 17 showed that 51 % of the patients with a histologically proven or presumed diagnosis of IPMN were smokers and demonstrated that there were no difference in the rate of smoking history between the controls and patients with IPMN. Also in support of our finding, they demonstrated that smoking history was associated with the development of main-duct type IPMN. Especially in the subgroup of patients who had a histologically diagnosed IPMN, obtained by EUS or surgical specimens, this association was stronger. This observation could be partly a result of the fact that the majority of the patients with a mainduct IPMN undergo a surgical resection according to the Sendai resection criteria.
Although main-duct IPMNs have a significant risk of progression to invasive carcinoma and despite a higher rate of smoking history we found in patients diagnosed with mainduct type IPMN, our results did not demonstrate any difference in histologic degree of dysplasia in these IPMNs between smokers and nonsmokers. This difference may be a consequence of the different genetic and epigenetic alterations in the two diseases. Although certain driver genes such as KRAS are known to be important in both IPMN associated cancer and non-IPMN-associated cancer, genetic alterations such as GNAS are unique to IPMN tumorigenesis. 25 -27 In this regard, tobacco carcinogens may differentially alter the unique genetic and epigenetic pathways involved in tumor initiation and progression.
Our study also shows that tobacco consumption is not an independent risk factor for development of high-grade dysplasia or invasive carcinoma in branch-duct IPMN. In a study by Nagai et al., rate of smoking was not significantly associated with malignancy in branch and mixed-type IPMN. 28 Sturm et al. 29 , in their series of 274 surgically resected IPMN, demonstrated that smoking history in obese patients is not associated with malignancy in branch and main-duct type IPMN. While many studies have merged invasive carcinoma and high-grade dysplasia into the term "malignancy," we separately considered the two conditions in our study. By multivariate analysis, the presence of a mural nodule on preoperative imaging predicted invasive carcinoma, but not high-grade dysplasia.
It should be noted that our study, owing to its retrospective nature, had some limitations, including the lack of quantitative smoking information. In addition, information on the number of tobacco-free years was absent for previous smokers. Although the quantity of tobacco exposure is believed to be associated with the development of pancreatic cancer, a recent study demonstrated that the number of pack-years smoking was not associated with development of IPMN. 17 More precise investigation is required to investigate the effect of the duration and amount of smoking exposure on histologic grades of IPMN. Moreover, smoking history is likely to be underreported by patients, which could possibly bias our results. In addition, our study suffers from selection bias because only patients that underwent resection for IPMN were analyzed. Patients being followed for presumed IPMN at our institution obviously lack pathologic confirmation of their diagnosis. Despite these limitations, this study is the largest study that confirms findings from prior, smaller studies that smoking is not associated with an increased risk of high-grade dysplasia or invasive adenocarcinoma in patients with IPMNs.
In conclusion, positive smoking history in patients with IPMN is more common in patients undergoing resection of main-duct IPMN but does not appear to cause a greater risk of harboring high-grade dysplasia or associated invasive carcinoma. Thus, based on our study, smoking history should not alter the management of patients with IPMNs.
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